Affiliation: University of California
- Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case seriesJeffrey Wolf
Myeloma Program, Hematologic Malignancies, University of California, San Francisco, CA 94143 0324, USA
Clin Adv Hematol Oncol 6:755-60. 2008..Favorable observed response rates with bortezomib retreatment suggest that it may be a viable option for relapsed or refractory multiple myeloma, even in patients previously exposed to bortezomib...